Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine sulfate liposome injection (Talon Therapeutics)
- Development stage
- Phase 2
- Lead developer
- Assertio
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Vincristine sulfate liposome injection (Marqibo) is a sphingomyelin/cholesterol liposome-encapsulated formulation of the vinca alkaloid vincristine sulfate. This nanoparticle delivery system is designed to overcome the dosing and pharmacokinetic limitations of standard vincristine by prolonging the drug's circulation time and enhancing its accumulation within tumor tissues via the enhanced permeability and retention (EPR) effect. Once at the tumor site, the liposomes release vincristine, which binds to tubulin and inhibits microtubule polymerization, leading to mitotic arrest in the metaphase and subsequent apoptosis. It was originally developed by Talon Therapeutics and later acquired by Spectrum Pharmaceuticals (now part of Assertio). The drug is primarily indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse.
- Brand names
- Marqibo
- Other names
- liposomal vincristinevincristine sulfate liposomevincristine liposomalliposomal vincristine sulfate
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vincristine sulfate liposome injection (Talon Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine sulfate liposome injection (Talon Therapeutics).